A polypeptide comprising the amino acid of an n-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
CA 2326388 C · Owner: Tuomanen, Elaine I. · Inventors: Wizemann, Theresa M.; Koenig, Scott; Johnson, Leslie Sydnor
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention provides an isolated polypeptide comprising an amino acid sequence of an N-terminal choline binding protein A truncate in which the amino acid sequence is set forth in any of SEQ ID NOS: 1,3-7 or 9-11, including fragments, mutants, variants analogs, or derivatives, thereof. , Also this invention provides isolated polypeptides comprising an amino acid sequence of a N-terminal choline binding protein A truncate wherein the amino , acid is set forth in SEQ ID NO 24 wherein the polypeptide retains its native tertiary structure and methods of preparation. This invention provides an isolated polypeptide comprising an amino acid sequence of an N-terminal choline binding …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 7, 1999 and granted February 4, 2014. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 7, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 7, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.